224 related articles for article (PubMed ID: 32533623)
41. Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism.
Cho KD; Paek J; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2014; 28(2):429-36. PubMed ID: 24372863
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015).
Lottati M; Bruyette DS
J Am Vet Med Assoc; 2018 Jun; 252(11):1403-1408. PubMed ID: 29772978
[TBL] [Abstract][Full Text] [Related]
44. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Mantis P; Lamb CR; Witt AL; Neiger R
Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
[TBL] [Abstract][Full Text] [Related]
45. Comparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with trilostane.
Boretti F; Musella C; Burkhardt W; Kuemmerle-Fraune C; Riond B; Reusch C; Sieber-Ruckstuhl N
BMC Vet Res; 2018 Dec; 14(1):417. PubMed ID: 30591042
[TBL] [Abstract][Full Text] [Related]
46. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy.
Witt AL; Neiger R
Vet Rec; 2004 Mar; 154(13):399-400. PubMed ID: 15083974
[No Abstract] [Full Text] [Related]
47. Use of the urine cortisol: creatinine ratio to monitor treatment response in dogs with pituitary-dependent hyperadrenocorticism.
Guptill L; Scott-Moncrieff JC; Bottoms G; Glickman L; Johnson M; Glickman N; Nelson R; Bertoy E
J Am Vet Med Assoc; 1997 Apr; 210(8):1158-61. PubMed ID: 9108922
[TBL] [Abstract][Full Text] [Related]
48. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane.
Reusch CE; Sieber-Ruckstuhl N; Wenger M; Lutz H; Perren A; Pospischil A
Vet Rec; 2007 Feb; 160(7):219-24. PubMed ID: 17308018
[TBL] [Abstract][Full Text] [Related]
49. Cushing's disease in dogs: cabergoline treatment.
Castillo VA; Gómez NV; Lalia JC; Cabrera Blatter MF; García JD
Res Vet Sci; 2008 Aug; 85(1):26-34. PubMed ID: 17910968
[TBL] [Abstract][Full Text] [Related]
50. Haptoglobin concentrations in dogs undergoing trilostane treatment for hyperadrenocorticism.
McGrotty YL; Arteaga A; Knottenbelt CM; Ramsey IK; Eckersall PD
Vet Clin Pathol; 2005 Sep; 34(3):255-8. PubMed ID: 16134074
[TBL] [Abstract][Full Text] [Related]
51. Hyperadrenocorticism in a dog due to ectopic secretion of adrenocorticotropic hormone.
Galac S; Kooistra HS; Voorhout G; van den Ingh TS; Mol JA; van den Berg G; Meij BP
Domest Anim Endocrinol; 2005 Apr; 28(3):338-48. PubMed ID: 15760674
[TBL] [Abstract][Full Text] [Related]
52. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats.
Burkhardt WA; Guscetti F; Boretti FS; Ivos Todesco A; Aldajarov N; Lutz TA; Reusch CE; Sieber-Ruckstuhl NS
Domest Anim Endocrinol; 2011 Apr; 40(3):155-64. PubMed ID: 21194873
[TBL] [Abstract][Full Text] [Related]
53. Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane.
García San José P; Arenas Bermejo C; Alonso-Miguel D; González Sanz S; Clares Moral I; Portero Fuentes M; Pérez-Alenza MD
Vet Rec; 2022 Aug; 191(3):e1630. PubMed ID: 35460587
[TBL] [Abstract][Full Text] [Related]
54. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Kenefick SJ; Neiger R
J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
[TBL] [Abstract][Full Text] [Related]
55. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis.
Teshima T; Hara Y; Takekoshi S; Nezu Y; Harada Y; Yogo T; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):32-44. PubMed ID: 19041802
[TBL] [Abstract][Full Text] [Related]
56. Effects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism.
Sieber-Ruckstuhl N; Salesov E; Quante S; Riond B; Rentsch K; Hofmann-Lehmann R; Reusch C; Boretti F
BMC Vet Res; 2017 Sep; 13(1):279. PubMed ID: 28870207
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic contribution of individual components of adrenal function tests to diagnose canine hyperadrenocorticism.
Jaffey JA; Hess RS; Webster CR; Blois SL; Hostnik ET; Heilmann RM; Jacobs C; Steiner JM; Reusch CE; Rogers E; Royal A; Piech T; Musella C; Carvalho L; Fink MJ; Motta GE; Kilkucki SN; Cigarro A; Roedler FS; Seidel T; DeClue AE
Vet J; 2020 Sep; 263():105520. PubMed ID: 32928489
[TBL] [Abstract][Full Text] [Related]
58. Persistent isolated hypocortisolism following brief treatment with trilostane.
Ramsey IK; Richardson J; Lenard Z; Tebb AJ; Irwin PJ
Aust Vet J; 2008 Dec; 86(12):491-5. PubMed ID: 19076773
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic utility of clinical and laboratory test parameters for differentiating between sudden acquired retinal degeneration syndrome and pituitary-dependent hyperadrenocorticism in dogs.
Oh A; Foster ML; Williams JG; Zheng C; Ru H; Lunn KF; Mowat FM
Vet Ophthalmol; 2019 Nov; 22(6):842-858. PubMed ID: 30864251
[TBL] [Abstract][Full Text] [Related]
60. Trilostane in dogs.
Ramsey IK
Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):269-83. PubMed ID: 20219488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
